HK1223307A1 - 新型化合物和其用途 - Google Patents

新型化合物和其用途 Download PDF

Info

Publication number
HK1223307A1
HK1223307A1 HK16111737.7A HK16111737A HK1223307A1 HK 1223307 A1 HK1223307 A1 HK 1223307A1 HK 16111737 A HK16111737 A HK 16111737A HK 1223307 A1 HK1223307 A1 HK 1223307A1
Authority
HK
Hong Kong
Prior art keywords
diseases
pharmaceutical compositions
compounds
formulae
growth factor
Prior art date
Application number
HK16111737.7A
Other languages
English (en)
Chinese (zh)
Inventor
Ben C. Askew
Andrew Good
Winston Zapanta ONG
Pawel Wojciech Nowak
Original Assignee
Kala Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals, Inc. filed Critical Kala Pharmaceuticals, Inc.
Publication of HK1223307A1 publication Critical patent/HK1223307A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK16111737.7A 2013-05-30 2014-05-30 新型化合物和其用途 HK1223307A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361829117P 2013-05-30 2013-05-30
US61/829,117 2013-05-30
US201361898719P 2013-11-01 2013-11-01
US61/898,719 2013-11-01
PCT/US2014/040231 WO2014197313A2 (en) 2013-05-30 2014-05-30 Novel compounds and uses thereof

Publications (1)

Publication Number Publication Date
HK1223307A1 true HK1223307A1 (zh) 2017-07-28

Family

ID=52008726

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111737.7A HK1223307A1 (zh) 2013-05-30 2014-05-30 新型化合物和其用途

Country Status (7)

Country Link
US (5) US9988386B2 (enExample)
EP (1) EP3003314B1 (enExample)
JP (1) JP6557654B2 (enExample)
AU (1) AU2014275198B2 (enExample)
CA (1) CA2913417A1 (enExample)
HK (1) HK1223307A1 (enExample)
WO (1) WO2014197313A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913417A1 (en) * 2013-05-30 2014-12-11 Kala Pharmaceuticals, Inc. Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor
KR102563675B1 (ko) * 2014-09-30 2023-08-04 트랜지션즈 옵티칼 인코포레이티드 자외선 광 흡수제
WO2016086026A1 (en) * 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341771A2 (en) * 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
KR20090047509A (ko) 2006-08-04 2009-05-12 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 유도체 및 이의 용도
JPWO2008016131A1 (ja) * 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
EP2184285B1 (en) * 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009096435A1 (ja) * 2008-01-29 2009-08-06 Takeda Pharmaceutical Company Limited 縮合複素環誘導体およびその用途
WO2010032880A2 (en) 2008-09-19 2010-03-25 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
JP2010126530A (ja) * 2008-12-01 2010-06-10 Takeda Chem Ind Ltd 縮合複素環誘導体およびその用途
NZ741873A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
CA2913417A1 (en) * 2013-05-30 2014-12-11 Kala Pharmaceuticals, Inc. Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor

Also Published As

Publication number Publication date
US10544151B2 (en) 2020-01-28
EP3003314A4 (en) 2017-03-08
JP6557654B2 (ja) 2019-08-07
US20200157106A1 (en) 2020-05-21
US9988386B2 (en) 2018-06-05
EP3003314B1 (en) 2019-05-15
EP3003314A2 (en) 2016-04-13
AU2014275198B2 (en) 2017-04-13
US20210380588A1 (en) 2021-12-09
JP2016520617A (ja) 2016-07-14
CA2913417A1 (en) 2014-12-11
US10954244B2 (en) 2021-03-23
US10351570B2 (en) 2019-07-16
US20180251467A1 (en) 2018-09-06
WO2014197313A3 (en) 2015-04-16
US20190023710A1 (en) 2019-01-24
WO2014197313A2 (en) 2014-12-11
AU2014275198A1 (en) 2015-12-10
US20160137646A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
WO2014201127A3 (en) Urea derivatives and uses thereof
CL2015000628A1 (es) Derivados tricíclicos de quinolinas y de quinoxalinas.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
WO2015013635A3 (en) Inhibitors of transcription factors and uses thereof
WO2016029191A3 (en) Channel modulators
MX2017004579A (es) Estructuras fibrosas solubles y metodos para fabricarlas.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
BR112017002963A2 (pt) derivados citotóxicos de benzodiazepina
EP3122782A4 (en) Compositions and methods for treatment of diabetic macular edema
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
EP4268843A3 (en) Improved il-6 antibodies
EP3060143A4 (en) Maintenance of bronchial patency by local delivery of cytotoxic, cytostatic, or anti-neoplastic agent
WO2015108787A3 (en) Compositions and methods for the treatment of intraocular neovascularization and/or leakage
CL2015001318A1 (es) Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.
WO2015109135A3 (en) Articles with improved flame retardancy and/or melt dripping properties
IL250022B (en) 1-(pyrimidin-2-yl)-6-(heterocyclyl-carbonyl)-(indoline/2,3-dihydroazaindole) derivatives, process for their preparation and pharmaceutical compositions comprising them
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2017010422A (es) Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.
WO2016061555A3 (en) Novel small molecule anticancer agents
HK1223307A1 (zh) 新型化合物和其用途
EP3503873A4 (en) EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
WO2015029035A8 (en) SELECTIVE INHIBITORS OF α2 ISOFORM OF Na,K-ATPase AND USE FOR REDUCTION OF INTRA-OCULAR PRESSURE
MX381356B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.